Opthea Limited (NASDAQ:OPTEY) — Market Cap & Net Worth
Market Cap & Net Worth: Opthea Limited (OPTEY)
Opthea Limited (NASDAQ:OPTEY) has a market capitalization of $3.42 Million ($3.42 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29014 globally and #5694 in its home market, demonstrating a -59.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Opthea Limited's stock price $0.02 by its total outstanding shares 170997272 (171.00 Million). Analyse OPTEY operating cash flow to see how efficiently the company converts income to cash.
Opthea Limited Market Cap History: 2025 to 2026
Opthea Limited's market capitalization history from 2025 to 2026. Data shows growth from $4.02 Million to $3.42 Million (0.00% CAGR).
Opthea Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Opthea Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
160.74x
Opthea Limited's market cap is 160.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $4.02 Million | $25.00K | -$162.79 Million | 160.74x | N/A |
Competitor Companies of OPTEY by Market Capitalization
Companies near Opthea Limited in the global market cap rankings as of May 4, 2026.
Key companies related to Opthea Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Opthea Limited Historical Marketcap From 2025 to 2026
Between 2025 and today, Opthea Limited's market cap moved from $4.02 Million to $ 3.42 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.42 Million | -14.89% |
| 2025 | $4.02 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Opthea Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.42 Million USD |
| MoneyControl | $3.42 Million USD |
| MarketWatch | $3.42 Million USD |
| marketcap.company | $3.42 Million USD |
| Reuters | $3.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Opthea Limited
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more